NCT02168361View on ClinicalTrials.gov

The SIM-SOF Trial for Hepatitis C

PHASE4CompletedINTERVENTIONAL
Enrollment

93

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

April 30, 2015

Conditions
Chronic Hepatitis C
Interventions
DRUG

Pegylated Interferon alfa-2b

1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total

DRUG

Simeprevir

150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks

DRUG

Ribavirin

1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir

DRUG

Sofosbuvir

12 weeks of combination sofosbuvir and simeprevir

Trial Locations (1)

30309

Center for Hepatitis C, Atlanta

All Listed Sponsors
lead

Center For Hepatitis C, Atlanta, GA

OTHER

NCT02168361 - The SIM-SOF Trial for Hepatitis C | Biotech Hunter | Biotech Hunter